Literature DB >> 26691146

Operative Versus Nonoperative Management of Nonfunctioning Pancreatic Neuroendocrine Tumors.

Irene Y Zhang1, Jing Zhao1, Carlos Fernandez-Del Castillo1, Yvonne Braun1, Shadi Razmdjou1, Andrew L Warshaw1, Keith D Lillemoe1, Cristina R Ferrone2.   

Abstract

INTRODUCTION: Surgical resection is the only curative treatment for pancreatic neuroendocrine tumors (PNETs), but pancreatic operations carry a significant morbidity. We investigated whether the resection of small, asymptomatic nonfunctioning PNETs is beneficial. Clinicopathologic factors were retrospectively reviewed for all PNET cases from 1998 to 2014.
METHODS: Kaplan-Meier survival and multivariable regression analyses were performed. A total of 249 patients had nonfunctioning PNETs with adequate follow-up, of whom 193 were resected and 56 were observed. Median age was 56 years, and 48 % of the patients were female.
RESULTS: Overall, the resected patients had a significantly longer survival (OS) (p = 0.001). However, for the patients with PNETs ≤2.5 cm in size and without metastasis at presentation, tumor size significantly modified the effect of resection on overall survival (p < 0.05). The protective effect of resection increased as tumor size increased. An operation became a significant predictor of overall survival for tumors >1.5 cm (p = 0.050 or less for larger tumors) but was not significant for tumors <1.5 cm (p = 0.317 or more for smaller tumors), controlling for age-adjusted Charlson comorbidity index.
CONCLUSION: Resection of nonfunctioning PNETs over 1.5 cm is independently and significantly associated with a longer survival. However, the benefit of resection for tumors under 1.5 cm is unclear.

Entities:  

Keywords:  Nonfunctioning; Pancreatic neuroendocrine tumor; Resection; Size; Surgery

Mesh:

Year:  2015        PMID: 26691146     DOI: 10.1007/s11605-015-3043-5

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  17 in total

1.  Surgical resection provides an overall survival benefit for patients with small pancreatic neuroendocrine tumors.

Authors:  Susan M Sharpe; Haejin In; David J Winchester; Mark S Talamonti; Marshall S Baker
Journal:  J Gastrointest Surg       Date:  2014-08-26       Impact factor: 3.452

2.  Clinical pathology of endocrine tumors of the pancreas. Analysis of autopsy cases.

Authors:  W Kimura; A Kuroda; Y Morioka
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

3.  A single institution's 26-year experience with nonfunctional pancreatic neuroendocrine tumors: a validation of current staging systems and a new prognostic nomogram.

Authors:  Trevor A Ellison; Christopher L Wolfgang; Chanjuan Shi; John L Cameron; Peter Murakami; Liew Jun Mun; Aatur D Singhi; Toby C Cornish; Kelly Olino; Zina Meriden; Michael Choti; Luis A Diaz; Timothy M Pawlik; Richard D Schulick; Ralph H Hruban; Barish H Edil
Journal:  Ann Surg       Date:  2014-02       Impact factor: 12.969

4.  Implications of incidentally discovered, nonfunctioning pancreatic endocrine tumors: short-term and long-term patient outcomes.

Authors:  Alex B Haynes; Vikram Deshpande; Thun Ingkakul; Parsia A Vagefi; Jackie Szymonifka; Sarah P Thayer; Cristina R Ferrone; Jennifer A Wargo; Andrew L Warshaw; Carlos Fernández-del Castillo
Journal:  Arch Surg       Date:  2011-05

5.  Tumor size correlates with malignancy in nonfunctioning pancreatic endocrine tumor.

Authors:  Rossella Bettini; Stefano Partelli; Letizia Boninsegna; Paola Capelli; Stefano Crippa; Paolo Pederzoli; Aldo Scarpa; Massimo Falconi
Journal:  Surgery       Date:  2011-07       Impact factor: 3.982

Review 6.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States.

Authors:  James C Yao; Manal Hassan; Alexandria Phan; Cecile Dagohoy; Colleen Leary; Jeannette E Mares; Eddie K Abdalla; Jason B Fleming; Jean-Nicolas Vauthey; Asif Rashid; Douglas B Evans
Journal:  J Clin Oncol       Date:  2008-06-20       Impact factor: 44.544

7.  Basing treatment strategy for non-functional pancreatic neuroendocrine tumors on tumor size.

Authors:  Yoji Kishi; Kazuaki Shimada; Satoshi Nara; Minoru Esaki; Nobuyoshi Hiraoka; Tomoo Kosuge
Journal:  Ann Surg Oncol       Date:  2014-04-18       Impact factor: 5.344

8.  Pancreatic neuroendocrine tumors: the impact of surgical resection on survival.

Authors:  Joshua S Hill; James T McPhee; Theodore P McDade; Zheng Zhou; Mary E Sullivan; Giles F Whalen; Jennifer F Tseng
Journal:  Cancer       Date:  2009-02-15       Impact factor: 6.860

9.  Cytological differentiation of asymptomatic pancreatic islet cell tumours in autopsy material.

Authors:  L Grimelius; G T Hultquist; B Stenkvist
Journal:  Virchows Arch A Pathol Anat Histol       Date:  1975

10.  Microvascular density and hypoxia-inducible factor pathway in pancreatic endocrine tumours: negative correlation of microvascular density and VEGF expression with tumour progression.

Authors:  A Couvelard; D O'Toole; H Turley; R Leek; A Sauvanet; C Degott; P Ruszniewski; J Belghiti; A L Harris; K Gatter; F Pezzella
Journal:  Br J Cancer       Date:  2005-01-17       Impact factor: 7.640

View more
  11 in total

1.  Robotic enucleations of pancreatic benign or low-grade malignant tumors: preliminary results and comparison with robotic demolitive resections.

Authors:  Ilenia Bartolini; Lapo Bencini; Marco Bernini; Marco Farsi; Massimo Calistri; Mario Annecchiarico; Luca Moraldi; Andrea Coratti
Journal:  Surg Endosc       Date:  2018-11-12       Impact factor: 4.584

2.  The Landmark Series: Pancreatic Neuroendocrine Tumors.

Authors:  Jordan M Cloyd; George A Poultsides
Journal:  Ann Surg Oncol       Date:  2020-09-18       Impact factor: 5.344

Review 3.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

4.  National Rise of Primary Pancreatic Carcinoid Tumors: Comparison to Functional and Nonfunctional Pancreatic Neuroendocrine Tumors.

Authors:  Gyulnara G Kasumova; Omidreza Tabatabaie; Mariam F Eskander; Abhishek Tadikonda; Sing Chau Ng; Jennifer F Tseng
Journal:  J Am Coll Surg       Date:  2016-12-10       Impact factor: 6.113

5.  The Role of Endoscopic Ultrasound-Guided Ki67 in the Management of Non-Functioning Pancreatic Neuroendocrine Tumors.

Authors:  YongYan Cui; Lauren G Khanna; Anjali Saqi; John P Crapanzano; James M Mitchell; Amrita Sethi; Tamas A Gonda; Michael D Kluger; Beth A Schrope; John Allendorf; John A Chabot; John M Poneros
Journal:  Clin Endosc       Date:  2019-07-15

Review 6.  What Are the Place and Modalities of Surgical Management for Pancreatic Neuroendocrine Neoplasms? A Narrative Review.

Authors:  Samuel Frey; Eric Mirallié; Maëlle Le Bras; Nicolas Regenet
Journal:  Cancers (Basel)       Date:  2021-11-26       Impact factor: 6.639

Review 7.  Multiple Endocrine Neoplasia Type 1: Latest Insights.

Authors:  Maria Luisa Brandi; Sunita K Agarwal; Nancy D Perrier; Kate E Lines; Gerlof D Valk; Rajesh V Thakker
Journal:  Endocr Rev       Date:  2021-03-15       Impact factor: 19.871

8.  Tumour diameter is not reliable for management of non-secreting pancreatic neuroendocrine tumours.

Authors:  Logan Mills; Panagiotis Drymousis; Yogesh Vashist; Christoph Burdelski; Andreas Prachalias; Parthi Srinivasan; Krishna Menon; Corina Cotoi; Saboor Khan; Judith Cave; Thomas Armstrong; Martin O Weickert; Jakob Izbicki; Joerg Schrader; Andreja Frilling; John K Ramage; Raj Srirajaskanthan
Journal:  Endocr Connect       Date:  2017-11       Impact factor: 3.335

Review 9.  Current Management of Pancreatic Neuroendocrine Tumors: From Demolitive Surgery to Observation.

Authors:  Ilenia Bartolini; Lapo Bencini; Matteo Risaliti; Maria Novella Ringressi; Luca Moraldi; Antonio Taddei
Journal:  Gastroenterol Res Pract       Date:  2018-07-22       Impact factor: 2.260

10.  Non-functional pancreatic neuroendocrine tumours: ATRX/DAXX and alternative lengthening of telomeres (ALT) are prognostically independent from ARX/PDX1 expression and tumour size.

Authors:  Wenzel M Hackeng; Lodewijk A A Brosens; Christopher M Heaphy; Aatur D Singhi; Joo Young Kim; Roderick O'Sullivan; You-Na Sung; Ta-Chiang Liu; Dengfeng Cao; Michelle Heayn; Jacqueline Brosnan-Cashman; Soyeon An; Folkert H M Morsink; Charlotte M Heidsma; Gerlof D Valk; Menno R Vriens; Els Nieveen van Dijkum; G Johan A Offerhaus; Koen M A Dreijerink; Herbert Zeh; Amer H Zureikat; Melissa Hogg; Kenneth Lee; David Geller; J Wallis Marsh; Alessandro Paniccia; Melanie Ongchin; James F Pingpank; Nathan Bahary; Muaz Aijazi; Randall Brand; Jennifer Chennat; Rohit Das; Kenneth E Fasanella; Asif Khalid; Kevin McGrath; Savreet Sarkaria; Harkirat Singh; Adam Slivka; Michael Nalesnik; Xiaoli Han; Marina N Nikiforova; Rita Teresa Lawlor; Andrea Mafficini; Boris Rusev; Vincenzo Corbo; Claudio Luchini; Samantha Bersani; Antonio Pea; Sara Cingarlini; Luca Landoni; Roberto Salvia; Massimo Milione; Michele Milella; Aldo Scarpa; Seung-Mo Hong
Journal:  Gut       Date:  2021-04-13       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.